Earnings History Data for Intercept Pharmaceuticals, Inc. (ICPT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
02-08-2023	PM		ICPT	Intercept Pharmaceuticals, Inc.	450.22	-0.14	-0.56	-0.68	Intercept Pharma beats Q2 top and bottom line estimates; updates FY23 outlook [8/2/2023 7:06 AM]	10.94	0.44 (4.19%)	11.40	0.90 (8.57%)	8.82 - 21.86	1,402,627	660,000	8,790
Intercept Pharma Q2 2023 Earnings Preview [8/1/2023 11:17 AM] Intercept Pharma beats Q2 top and bottom line estimates; updates FY23 outlook [8/2/2023 7:06 AM]
27-04-2023	PM	7:00 AM ET (Apr 27)	ICPT	Intercept Pharmaceuticals, Inc.	765.90	-0.77	-0.57	-0.58	Intercept Pharma GAAP EPS of -$0.77 misses by $0.15, revenue of $68M misses by $4.68M [4/27/2023 7:08 AM]	15.93	-2.41 (-13.17%)	18.00	-0.34 (-1.86%)	10.81 - 21.86	1,714,094	680,000	1,401
Intercept Pharma Q1 2023 Earnings Preview [4/26/2023 12:02 PM] Intercept Pharma GAAP EPS of -$0.77 misses by $0.15, revenue of $68M misses by $4.68M [4/27/2023 7:08 AM] Intercept Pharma off 11% on Q1 misses [4/27/2023 1:52 PM]
02-03-2023	PM	7:00 AM ET (Mar 2)	ICPT	Intercept Pharmaceuticals, Inc.	804.73	-0.42	-0.53	-1.23	Intercept Pharma GAAP EPS of -$0.50 misses by $0.26, revenue of $77.22M misses by $0.86M [3/2/2023 7:05 AM]	20.71	0.90 (4.54%)	19.75	-0.06 (-0.30%)	10.81 - 21.86	736,564	720,000	756
Intercept Pharma Q4 2022 Earnings Preview [3/1/2023 12:34 PM] Intercept Pharma GAAP EPS of -$0.50 misses by $0.26, revenue of $77.22M misses by $0.86M [3/2/2023 7:05 AM]
01-11-2022	PM	7:00 AM ET (Nov 1)	ICPT	Intercept Pharmaceuticals, Inc.	589.36	-3.04	5.11	-0.63	Intercept PharmaEPS of -$3.04, revenue of $77.59M [11/1/2022 7:09 AM]	15.74	1.88 (13.52%)	14.34	0.47 (3.39%)	10.81 - 21.25	1,499,910	630,000	289
Intercept PharmaEPS of -$3.04, revenue of $77.59M [11/1/2022 7:09 AM] Intercept Pharma rises 12% on strong Q3 sales of Ocaliva therapy [11/1/2022 11:41 AM] Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update [Nov-01-22 07:00AM] Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022 [Oct-31-22 04:05PM]
03-08-2022	PM	7:00 AM ET (Aug 3)	ICPT	Intercept Pharmaceuticals, Inc.	417.47	-0.68	-0.53	-0.33	Intercept Pharma GAAP EPS of -$0.68, revenue of $71.76M [8/3/2022 7:06 AM]	13.82	1.57 (12.82%)	12.39	0.14 (1.14%)	10.81 - 20.50	1,400,520	700,000	3,107
Intercept Pharma Q2 2022 Earnings Preview [8/2/2022 12:21 PM] Intercept Pharma GAAP EPS of -$0.68, revenue of $71.76M [8/3/2022 7:06 AM] Intercept Pharma up 13% following Q2 revenue increase, NASH NDA resubmission [8/3/2022 12:18 PM] Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update [Aug-03-22 07:00AM]
06-05-2022	PM	7:00 AM ET (May 6)	ICPT	Intercept Pharmaceuticals, Inc.	480.72	-0.58	-0.89	-1.22	Intercept Pharma GAAP EPS of -$0.58 beats by $0.37, revenue of $88.58M misses by $1.9M [5/6/2022 7:03 AM]	19.27	-0.32 (-1.63%)	19.27	0.0 (0.00%)	11.60 - 22.36	2,390,644	1,960,000	11,072
Intercept Pharma Q1 2022 Earnings Preview [5/5/2022 12:06 PM] Intercept Pharma to sell ex-U.S. rights for Ocaliva to Advanz Pharma [5/5/2022 8:11 AM] Intercept Pharma GAAP EPS of -$0.58 beats by $0.37, revenue of $88.58M misses by $1.9M [5/6/2022 7:03 AM] Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug [May-05-22 04:21PM] Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates [May-05-22 08:25AM] Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments [May-05-22 07:17AM] Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update [May-06-22 07:00AM] Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates [May-06-22 08:25AM]
02-03-2022	PM	7:00 AM ET (Mar 2)	ICPT	Intercept Pharmaceuticals, Inc.	421.34	-1.23	-1.25	-1.58	Intercept Pharma GAAP EPS of -$1.23 misses by $0.18, revenue of $92.4M beats by $0.31M [3/2/2022 7:02 AM]	13.55	-1.45 (-9.68%)	13.83	-1.17 (-7.80%)	11.60 - 25.27	1,867,867	750,000	21,588
Intercept Pharma Q4 2021 Earnings Preview [3/1/2022 11:59 AM] Intercept Pharma GAAP EPS of -$1.23 misses by $0.18, revenue of $92.4M beats by $0.31M [3/2/2022 7:02 AM] Intercept slips after another delay for NASH readout [3/2/2022 8:57 AM] Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update [Mar-02-22 07:00AM] 2 Biotech Stocks That Could Make You Richer [Mar-02-22 07:02AM] Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates [Mar-02-22 08:25AM]
03-11-2021	PM	7:00 AM ET (Nov 3)	ICPT	Intercept Pharmaceuticals, Inc.	493.86	-0.63	1.00	-2.01	Intercept Pharma EPS beats by $0.98, beats on revenue [11/3/2021 7:01 AM]	19.35	1.90 (10.89%)	18.44	0.99 (5.67%)	11.60 - 40.41	2,705,476	510,000	46,751
Intercept Pharma Q3 2021 Earnings Preview [11/2/2021 11:52 AM] Intercept Pharma EPS beats by $0.98, beats on revenue [11/3/2021 7:01 AM] Intercept Pharma rises 15% on Q3 earnings beat, boost in 2021 Ocaliva sales guidance [11/3/2021 10:27 AM] Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting [Nov-02-21 08:00AM] 5 Biotech Stocks With 105% to 386% Upside, According to Wall Street [Nov-03-21 05:51AM] Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update [Nov-03-21 07:00AM] Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates [Nov-03-21 08:15AM] Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call Transcript [Nov-03-21 03:31PM]
29-07-2021	PM	7:00 AM ET (Jul 29)	ICPT	Intercept Pharmaceuticals, Inc.	544.85	-0.33	-1.24	-1.92	Intercept Pharma EPS beats by $0.89, beats on revenue [7/29/2021 7:06 AM]	17.37	0.50 (2.96%)	18.10	1.23 (7.29%)	13.88 - 55.59	604,495	500,000	15,638
Intercept Pharma Q2 2021 Earnings Preview [7/28/2021 12:23 PM] Intercept Pharma EPS beats by $0.89, beats on revenue [7/29/2021 7:06 AM] Intercept Pharmaceuticals posts Q2 earnings beat on Ocaliva Strength, shares rise [7/29/2021 8:04 AM] Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update [Jul-29-21 07:00AM] Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates [Jul-29-21 08:15AM]
06-05-2021	PM	7:00 AM ET (May 6)	ICPT	Intercept Pharmaceuticals, Inc.	635.39	-1.22	-1.53	-2.86	Intercept Pharma EPS beats by $0.27, beats on revenue; narrows guidance [5/6/2021 7:06 AM]	17.01	-2.03 (-10.66%)	17.01	0.0 (0.00%)	16.81 - 95.98	1,831,775	880,000	19,653
Intercept Pharma EPS beats by $0.27, beats on revenue; narrows guidance [5/6/2021 7:06 AM] Intercept Pharmaceuticals, Inc. to Host Earnings Call [May-06-21 06:45AM] Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update [May-06-21 07:00AM] Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates [May-06-21 08:35AM]
25-02-2021	PM	7:00 AM ET (Feb 25)	ICPT	Intercept Pharmaceuticals, Inc.	927.75	-1.58	-1.55	-2.99	Intercept Pharma EPS misses by $0.09, misses on revenue [2/25/2021 7:05 AM]	23.02	-0.20 (-19.51%)	28.40	-0.20 (-0.70%)	23.01 - 98.03	2,185,220	785,468	2,623
Intercept Pharma EPS misses by $0.09, misses on revenue [2/25/2021 7:05 AM] Intercept Pharma Q4 2020 Earnings Preview [2/24/2021 12:32 PM] Intercept shares slide 6% following Q4 misses [2/25/2021 10:46 AM] Intercept Pharmaceuticals Inc (ICPT) Q4 2020 Earnings Call Transcript [Feb-25-21 12:00PM] Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update [Feb-25-21 07:00AM] Intercept Pharmaceuticals, Inc. to Host Earnings Call [Feb-25-21 06:30AM]
09-11-2020	PM	7:00 AM ET (Nov 9)	ICPT	Intercept Pharmaceuticals, Inc.	970.30	-2.01	-1.96	-2.59	Intercept Pharma EPS misses by $0.04, beats on revenue [11/9/2020 7:01 AM]	34.84	6.69 (23.77%)	29.50	1.35 (4.80%)	27.02 - 125.00	2,872,851	633,468	11,345

10-08-2020	PM	7:00 AM ET (Aug 10)	ICPT	Intercept Pharmaceuticals, Inc.	1,550	-1.92	-2.88	-2.28	Intercept Pharma EPS beats by $1.01, beats on revenue [8/10/2020 7:05 AM]	50.96	2.22 (4.54%)	50.00	1.25 (2.56%)	42.19 - 125.00	1,371,965	652,264	11,759